NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Weiss, Brian D., Wolters, Pamela L., Plotkin, Scott R., Widemann, Brigitte C., Tonsgard, James H., Blakeley, Jaishri, Allen, Jeffrey C., Schorry, Elizabeth, Korf, Bruce, Robison, Nathan J., Goldman, Stewart, Vinks, Alexander A., Emoto, Chie, Fukuda, Tsuyoshi, Robinson, Coretta T., Cutter, Gary, Edwards, Lloyd, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2021
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078274/
https://ncbi.nlm.nih.gov/pubmed/33507822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02220
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars